CORDIS
EU research results

CORDIS

English EN
Bio-orthogonal catalysis for cancer therapy

Bio-orthogonal catalysis for cancer therapy

Objective

THERACAT is an international and multidisciplinary consortium aiming at the training of 13 ESRs on the innovative topic of novel bio-orthogonal catalysis-based tools for cancer therapy. This ETN comprises 6 academic partners, 3 industrial partners active in the pharmaceutical market (1 large pharmaceutical company, Teva, and 2 SMEs, BiogelX and Tagworks) and 3 partners with focus on science communication (Cancer research UK), gender and minorities (UAB-Observatory for Equality) and management and entrepreneurship (ESADE business school). The combination of academic, private and society-involved organisations will provide a broad training for the 13 ESRs recruited, equipping them with the necessary skills to succeed as scientists, industrial researchers and entrepreneurs.
The development of novel cancer therapies is a major challenge for academic research and pharmaceutical industries. THERACAT aims to establish a training programme focused on the development of THERApeutic CATalysts. In this strategy, materials bearing a catalytic unit are delivered to the tumour and subsequently non-active prodrugs are administered. The prodrugs are non-toxic and therefore generate limited side effects. Only at the tumour site the catalytic particles convert the prodrugs into active compounds that generate a therapeutic effect. This approach presents several advantages on the classical drug delivery paradigm including limited side effects and prolonged efficacy.
This multidisciplinary research programme will be the setting for the training of 13 ESRs. The combination of the research expertise, the cutting-edge facilities and the complementary skills present in the consortium holds a great promise for the advancement of their careers, as well as of the knowledge of catalysis-based anticancer therapies and the development of marketable technologies and products.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA

Address

Carrer Baldiri Reixac Planta 2a 10-12
08028 Barcelona

Spain

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 247 872,96

Participants (8)

Sort alphabetically

Sort by EU Contribution

Expand all

TECHNISCHE UNIVERSITEIT EINDHOVEN

Netherlands

EU Contribution

€ 758 603,49

RIJKSUNIVERSITEIT GRONINGEN

Netherlands

EU Contribution

€ 255 374,28

UNIVERSITAT BASEL

Switzerland

EU Contribution

€ 265 226,76

THE UNIVERSITY OF EDINBURGH

United Kingdom

EU Contribution

€ 546 575,76

TEL AVIV UNIVERSITY

Israel

EU Contribution

€ 520 601,04

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

Israel

EU Contribution

€ 260 300,52

TAGWORKS PHARMACEUTICALS BV

Netherlands

EU Contribution

€ 255 374,28

BIOGELX LIMITED

United Kingdom

EU Contribution

€ 273 287,88

Project information

Grant agreement ID: 765497

Status

Ongoing project

  • Start date

    1 March 2018

  • End date

    28 February 2022

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 3 383 216,97

  • EU contribution

    € 3 383 216,97

Coordinated by:

FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA

Spain